by Ryan Oglesby | Aug 1, 2024 | News
New partnership aims to improve the management of neurodegeneration associated with traumatic brain injuries from contact sports and military service CereMark Pharma, a clinical-stage radiopharmaceutical company specializing in the development of novel Positron...
by Ryan Oglesby | Dec 8, 2023 | News
CereMark Prepares for Pivotal Phase 3 Clinical Trial for Prediction of Cognitive Decline in Alzheimer’s Disease, CTE and Other Neurodegenerative Diseases New York, New York – June 28, 2023 CereMark Pharma LLC (“CereMark”) today announced that it has...
by Ryan Oglesby | Oct 7, 2023 | News
Los Angeles, California – August 2, 2022: CereMark Pharma LLC (“CereMark”) today announced that additional patents have been awarded to the University of California at Los Angeles (‘UCLA”) associated with a unique, selective imaging biomarker,...
by Ryan Oglesby | Oct 7, 2023 | News
CereMark clinical research studies show that Flornaptitril binds with both tau aggregates and beta amyloid plaque in the brain to enhance PET scan imaging. The distribution patterns of these pathological proteins are significant in both Chronic Traumatic...
